Proteomic Profiles of Left Atrial Volume and Its Influence on Response to Spironolactone: Findings from the HOMAGE Trial and STANISLAS Cohort
European Journal of Heart Failure · 2024
DOI: 10.1002/ejhf.3202 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2024. Verfasst von Masatake Kobayashi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, Franc…. Hauptthemen laut MEDLINE: Spironolactone, Heart Atria, Proteomics, Heart Failure. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Union Commission's Seventh Framework programme, Netherlands Cardiovascular Research Initiative, Dutch Heart Foundation, Dutch Cardiovascular AllianceCVON2016-Early HFPEF.
Abstract (Originalsprache)
Aims
High left ventricular filling pressure increases left atrial volume and causes myocardial fibrosis, which may decrease with spironolactone. We studied clinical and proteomic characteristics associated with left atrial volume indexed by body surface area (LAVi), and whether LAVi influences the response to spironolactone on biomarker expression and clinical variables. Methods and results In the HOMAGE trial, where people at risk of heart failure were randomized to spironolactone or control, we analysed 421 participants with available LAVi and 276 proteomic measurements (Olink) at baseline, month 1 and 9 (mean age 73 ± 6 years; women 26%; LAVi 32 ± 9 ml/m2). Circulating proteins associated with LAVi were also assessed in asymptomatic individuals from a population-based cohort (STANISLAS; n = 1640; mean age 49 ± 14 years; women 51%; LAVi 23 ± 7 ml/m2). In both studies, greater LAVi was significantly associated with greater left ventricular masses and volumes. In HOMAGE, after adjustment and correction for multiple testing, greater LAVi was associated with higher concentrations of matrix metallopeptidase-2 (MMP-2), insulin-like growth factor binding protein-2 (IGFBP-2) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) (false discovery rates [FDR] <0.05). These associations were externally replicated in STANISLAS (all FDR <0.05). Among these biomarkers, spironolactone decreased concentrations of MMP-2 and NT-proBNP, regardless of baseline LAVi (pinteraction > 0.10). Spironolactone also significantly reduced LAVi, improved left ventricular ejection fraction, lowered E/e', blood pressure and serum procollagen type I C-terminal propeptide (PICP) concentration, a collagen synthesis marker, regardless of baseline LAVi (pinteraction > 0.10).
Conclusion
In individuals without heart failure, LAVi was associated with MMP-2, IGFBP-2 and NT-proBNP. Spironolactone reduced these biomarker concentrations as well as LAVi and PICP, irrespective of left atrial size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Université de Lorraine, INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France.
- Department of Cardiology, Tokyo Medical University Hospital, Tokyo, Japan.
- Cardiovascular Research and Development Center, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.
- Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands.
- School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK.
- Department of Cardiology, University of Hull, Castle Hill Hospital, Yorkshire, UK.
Förderung
- European Union Commission's Seventh Framework programme
- Netherlands Cardiovascular Research Initiative
- Dutch Heart Foundation, Dutch Cardiovascular AllianceCVON2016-Early HFPEF
- CVON She-PREDICTS
- FWO
- Instituto de Salud Carlos III
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
Kobayashi, M., Ferreira, J. P., Duarte, K., Bresso, E., Huttin, O., Bozec, E., Brunner La Rocca, H. P., Delles, C., Clark, A. L., Edelmann, F., González, A., Heymans, S., Pellicori, P., Petutschnigg, J., Verdonschot, J. A. J., Rossignol, P., Cleland, J. G. F., Zannad, F., Girerd, N., & HOMAGE Trial Committees and Investigators (2024). Proteomic Profiles of Left Atrial Volume and Its Influence on Response to Spironolactone: Findings from the HOMAGE Trial and STANISLAS Cohort. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3202
Vancouver
Kobayashi M, Ferreira JP, Duarte K, Bresso E, Huttin O, Bozec E, et al. Proteomic Profiles of Left Atrial Volume and Its Influence on Response to Spironolactone: Findings from the HOMAGE Trial and STANISLAS Cohort. European Journal of Heart Failure. 2024. doi:10.1002/ejhf.3202
BibTeX
@article{Kobayashi2024,
author = {Kobayashi, Masatake and Ferreira, João Pedro and Duarte, Kevin and Bresso, Emmanuel and Huttin, Olivier and Bozec, Erwan and Brunner La Rocca, Hans-Peter and Delles, Christian and Clark, Andrew L and Edelmann, Frank and González, Arantxa and Heymans, Stephane and Pellicori, Pierpaolo and Petutschnigg, Johannes and Verdonschot, Job A J and Rossignol, Patrick and Cleland, John G F and Zannad, Faiez and Girerd, Nicolas and HOMAGE Trial Committees and Investigators, HOMAGE Trial Committees and Investigators},
title = {Proteomic Profiles of Left Atrial Volume and Its Influence on Response to Spironolactone: Findings from the HOMAGE Trial and STANISLAS Cohort},
journal = {European Journal of Heart Failure},
year = {2024},
doi = {10.1002/ejhf.3202}
}
EUVIMED